<DOC>
	<DOCNO>NCT02559921</DOCNO>
	<brief_summary>This study evaluate rabies virus neutralize antibody ( RVNA ) activity , safety tolerability rhRIG vs. HRIG combination rabies vaccine human use ( Vero cell ) healthy adult subjects.The study 7 groups.Subjects receive rhRIG（20 IU/kg）only , rhRIG（40 IU/kg）only , HRIG（20 IU/kg）only , rhRIG（20 IU/kg）in combination rabies vaccine human use , rhRIG（40 IU/kg）in combination rabies vaccine human use , HRIG（20 IU/kg）in combination rabies vaccine human use , placebo combination rabies vaccine human use , respectively .</brief_summary>
	<brief_title>Safety Immunogenicity Study Recombinant Human Rabies Immunoglobin ( rhRIG ) Combination With Rabies Vaccine Human Use With Human Rabies Immune Globulin ( HRIG ) Combination With Rabies Vaccine Human Use Healthy Adult Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female subject age least 18 year 55 year ; 2 . According medical history , physical examination clinical judgment investigator enrollment , subject significant health problem , health status medication treatment remain stable ; 3 . Subjects spouses use adequate contraceptive method screen day Day 90 ; 4 . Male subject must agree donate sperm first day enrollment Day 90 ; 5 . Subjects sign write Informed Consent Form ; 1 . Previous exposure immunization history rabies ( rabies vaccine and/or immunoglobulin ) ; 2 . According clinical judgment investigator , subject clinically significant acute disease infection , include pyrexia ( &gt; 37.0℃ ) within 2 week initial dose ; 3 . After review medical history physical examination result , found subject medical history abnormality heart , liver , kidney , blood , digestive tract , nervous system , spirit metabolism ; 4 . Subjects pregnant plan become pregnant breastfeeding study ; 5 . According judgment investigator , subject clinically significant immunodeficiency medical history and/or family history autoimmune disease ; 6 . According judgment investigator , subject know suspect clinically significant anaphylaxis hypersensitivity reaction ; 7 . Immunization arrange subject within next 3 month initial dose ; 8 . Subjects use immunosuppressive preparation immunomodulating agent 14 day within 6 month initial dose study drug ; 9 . Subjects use hormone agent within 3 day initial dose ; 10 . Subjects donate blood lose lot blood within 56 day initial dose ; 11 . Subjects donate plasma within 7 day initial dose ; 12 . Subjects receive transfusion blood blood product within 6 month initial dose ; 13 . It suspect subject follow study procedure ; 14 . Intake alcohol within 12 hour initial dose ; 15 . Subjects smoke 20 cigarette day ; 16 . Subjects obviously allergic antibiotic ; 17 . Any condition may affect trial assessment discretion investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Recombinant Human Rabies Immunoglobin ( rhRIG )</keyword>
</DOC>